The BAP1 Knockout HeLa Polyclonal Cells are a genetically engineered polyclonal cell population generated by CRISPR/Cas9-mediated disruption of the BAP1 gene in the HeLa cervical adenocarcinoma cell line. This polyclonal knockout model provides a heterogeneous population of cells with targeted loss-of-function mutations in BAP1, enabling robust investigation of BAP1-dependent cellular processes without the clonal selection artifacts associated with monoclonal lines.
HeLa cells are a well-established immortalized human cervical adenocarcinoma line, originally derived from an HPV18-positive tumor. They serve as a versatile epithelial cancer model extensively used in cancer biology, protein expression, and signaling studies. The HeLa background provides a reproducible platform for examining tumor suppressor gene function, with the added complexity of viral oncoprotein interactions that may intersect with chromatin regulation and DNA damage signaling pathways.
BAP1 (BRCA1-associated protein 1) encodes a nuclear deubiquitinase (DUB) that specifically removes monoubiquitin from lysine 119 of histone H2A (H2A K119Ub), counteracting Polycomb repressive complex 1 (PRC1)-mediated gene silencing. The tumor suppressor functions of BAP1 are executed through a multi-protein complex including ASXL1/2 and HCFC1, which targets BAP1 to chromatin and modulates its enzymatic activity. Upstream, BAP1 function is regulated by DNA damage-activated ATM/ATR kinases, linking chromatin remodeling to the DNA damage response. Downstream, BAP1-mediated deubiquitination influences the expression of Polycomb target genes, cell cycle regulators, and apoptosis mediators. Additional interacting partners such as FOXK1/2, OGT, and BRCA1/BARD1 further integrate BAP1 into networks controlling transcriptional regulation, metabolic sensing, and genome stability. Loss of BAP1 activity leads to aberrant retention of H2A K119Ub, altered H3K27me3 distribution, and dysregulation of gene programs that promote oncogenesis.
In the HeLa cervical adenocarcinoma context, BAP1 disruption provides a powerful system to dissect the tumor suppressor mechanisms that are frequently inactivated in cancers such as uveal melanoma, malignant mesothelioma, and renal cell carcinoma. The polyclonal knockout population recapitulates the genetic heterogeneity of BAP1 loss found in patient tumors, enabling studies of mutational effects on DNA damage repair, cell cycle progression, and apoptosis. The HPV18-positive background of HeLa cells also allows interrogation of potential viral-host interplay with BAP1-regulated chromatin modifications, offering insights into oncogenic cooperation.
Researchers can employ this BAP1 knockout model for a range of functional assays, including Western blotting to monitor global H2A K119Ub levels, RT-qPCR profiling of Polycomb target gene expression, and immunofluorescence detection of ??H2AX foci to assess DNA double-strand break repair kinetics. Colony formation and Annexin V apoptosis assays can evaluate clonogenic survival and programmed cell death, respectively, while drug sensitivity screens allow identification of therapeutic vulnerabilities in BAP1-deficient cells. These applications make the product suitable for drug discovery, mechanism-of-action studies, and target validation in BAP1-associated malignancies. For additional technical information, please contact Ascent Research.
